International Stroke Conference (ISC) 2026

New Orleans, Louisiana 04 February 2026 - 06 February 2026

EVT improves functional outcomes in select stroke patients

Results from the Oriental MeVo trial show that endovascular thrombectomy (EVT) within 24 hours of symptom onset significantly improves functional outcomes in individuals with medium vessel occlusion (MeVO) stroke and moderate-to-severe deficits.

EVT improves functional outcomes in select stroke patients

21 hours ago

Tenecteplase bests alteplase for distal occlusions

a day ago by

In the secondary analysis of the TASTE trial, tenecteplase is associated with better clinical outcomes than alteplase in individuals with distal vessel occlusions (DVOs).

Tenecteplase bests alteplase for distal occlusions

a day ago

CHOICE-2 strengthens case for administering intra-arterial lytic after thrombectomy

20 Feb 2026 by

For patients with acute ischaemic stroke caused by a large-vessel occlusion, infusing alteplase into the artery after successful endovascular thrombectomy is beneficial, conferring functional gains and reducing persistent hypoperfusion, as shown in the phase III open-label CHOICE-2 trial.

CHOICE-2 strengthens case for administering intra-arterial lytic after thrombectomy

20 Feb 2026

Novel loberamisal neuroprotectant boosts functional recovery from stroke

19 Feb 2026 by

Among patients with acute ischaemic stroke, administration of loberamisal, a novel neuroprotective agent, within 48 hours of symptom onset improves functional outcomes, according to the LAIS* trial presented at ISC 2026.

Novel loberamisal neuroprotectant boosts functional recovery from stroke

19 Feb 2026

Oral FXIa inhibitor reduces stroke recurrence without increasing major bleeding events

18 Feb 2026 by

The oral factor XIa (FXIa) inhibitor asundexian scores high for secondary prevention in patients with non-cardioembolic stroke or high-risk transient ischaemic attack (TIA) who are receiving standard antiplatelet therapy, having met its primary efficacy and safety endpoints in the phase III OCEANIC-STROKE trial.

Oral FXIa inhibitor reduces stroke recurrence without increasing major bleeding events

18 Feb 2026

GLP-1 RAs may lower long-term mortality risk in AIS patients

16 Feb 2026 by

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appears to contribute to a long-term reduced risk of death in patients with acute ischaemic stroke (AIS), suggests a study. However, less than 1 percent of these individuals have been prescribed GLP-1 RAs upon discharge.

GLP-1 RAs may lower long-term mortality risk in AIS patients

16 Feb 2026

Adjunct tirofiban improves functional outcomes in AIS

14 Feb 2026 by

Treatment with the short-acting glycoprotein IIb/IIIa inhibitor tirofiban after intravenous thrombolysis (IVT) results in significant improvements in 90-day functional outcomes among patients with acute ischaemic stroke, with no increase in haemorrhage or mortality, a study has shown.

Adjunct tirofiban improves functional outcomes in AIS

14 Feb 2026

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

13 Feb 2026 by

The use of intra-arterial (IA) alteplase following a successful endovascular thrombectomy (EVT) improves 90-day functional outcome in patients with large-vessel occlusion (LVO) acute ischaemic stroke compared with EVT-alone, according to the CHOICE 2* trial presented at ISC 2026.

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

13 Feb 2026